Last reviewed · How we verify
Ephedrine, continuous infusion
Ephedrine, a sympathomimetic amine marketed by the University of Parma, is used for its vasoconstrictive and cardiac effects. The drug's key strength lies in its well-established mechanism of action through alpha and beta-adrenergic receptor stimulation. A primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Ephedrine, continuous infusion |
|---|---|
| Sponsor | University of Parma |
| Drug class | Sympathomimetic amine |
| Target | Alpha and beta-adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
Pipeline indications
Common side effects
Drug interactions
- Monoamine oxidase inhibitors (MAOIs)
- Tricyclic antidepressants
- Beta-blockers
Key clinical trials
- Intravenous Administration of Magnesium Sulfate in Laparoscopic Hysterectomy Cases (NA)
- Ephedrine Versus Phenylephrine for Spinal Block - Related Hypotension in Cesarean Delivery
- Anesthesia Techniques, Neuroprotection and Surgical Field in FESS Under Controlled Hypotension (NA)
- Minimal Flow Anesthesia and Infection Risk (NA)
- Intraoperative Goal-directed Blood Pressure and Dexmedetomidine on Outcomes (PHASE4)
- Effects Of Anaesthesia on Intraocular Pressure in Robotic Prostate Surgery (NA)
- HIgh Versus STAndard Blood Pressure Target in Hypertensive High-risk Patients Undergoing Major Abdominal Surgery (NA)
- Intravenous Administration of Magnesium Sulfate in Hysterectomy Cases (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ephedrine, continuous infusion CI brief — competitive landscape report
- Ephedrine, continuous infusion updates RSS · CI watch RSS
- University of Parma portfolio CI